EBR Systems is developing ultrasound based wireless stimulation therapies.
Total raised: $135M
Investors 8
Funding Rounds 4
| Date | Series | Amount | Investors |
| 29.08.2019 | - | $30M | - |
| 15.11.2017 | - | $50M | - |
| 08.04.2015 | - | $20M | - |
| 30.07.2008 | - | $35M | - |
Mentions in press and media 22
| Date | Title | Description |
| 07.11.2025 | EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients | The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: The first two patients have now been enrolled in the WiSE... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 17.04.2025 | FDA Approves WiSE® System, World’s First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT | Every once in a while, a breakthrough doesn’t just advance medicine—it changes the conversation entirely. SUNNYVALE, Calif., April 17, 2025 /PRNewswire/ — EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which mar... |
| 04.06.2024 | Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation | MELBOURNE, Australia – 4 June 2024 – Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). ... |
| 26.10.2023 | Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology | SUNNYVALE, Calif., Oct. 26, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resyn... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation | EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) Syste... |
| 29.08.2019 | EBR Systems Raises $30M in Funding | The WiSE Cardiac Resynchronization Therapy (CRT) System. EBR Systems, Inc., a Sunnyvale, Calif.-based developer of a wireless cardiac pacing system for heart failure, raised $30M in funding. The round was led by Australian private equity fi... |
| 29.08.2019 | Daily funding roundup - August 28th, 2019 | AgroSpheres raised $4M; Salaryo picks up $5.5M; ReadMe landed $9M; EBR Systems closed $30M AgroSpheres: AgroSpheres is developing novel nanotechnologies aiming to set a new standard for bio-based delivery of active ingredients. AgroSpheres ... |
| 27.08.2019 | EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO | EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercia... |
| 27.08.2019 | EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO | - |
Show more